Clinical Trial Update: A Study to Evaluate the Safety and Efficacy of Polatuzumab Vedotin in Combination With Rituximab, Gemcitabine and Oxaliplatin Compared to Rituximab, Gemcitabine and Oxaliplatin Alone in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating polatuzumab vedotin in combination with rituximab, gemcitabine and oxaliplatin versus rituximab, gemcitabine and oxaliplatin alone in…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma

Drugs mentioned

• Gemcitabine (Gemcitabine)
• OXALIPLATIN (Oxaliplatin)
• Rituximab (rituximab)
• polatuzumab vedotin (polatuzumab vedotin)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Diffuse Large B-Cell Lymphoma | Phase 3 | Status: COMPLETED | Results posted: 2025-12-22